Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan in Advanced Solid Tumors
NCT07309770Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in solid tumor (advanced stage), extramammary Paget's disease (EMPD), urothelial carcinoma (UC), urachal cancer, sarcoma. Started Dec 2025; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
solid tumor (advanced stage)extramammary Paget's disease (EMPD)urothelial carcinoma (UC)urachal cancersarcoma
Beyond the preview
Go deeper on NCT07309770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309770.